Related Experiment Video

Updated: May 26, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from

Toni Terry1, Kalyani Raravikar, Nalurporn Chokrungvaranon

  • 1Division of Endocrinology, Phoenix VA Health Care System, 650 East Indian School Road, Phoenix, AZ 85012, USA. toni.terry@va.gov

Current Cardiology Reports
|December 14, 2011
PubMed

Insights

Intensive glucose control in diabetes may not benefit everyone. Individualized glycated hemoglobin goals are essential, considering factors like diabetes duration and existing vascular disease.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Diseases

Background:

  • Diabetes mellitus is a global health crisis, often leading to serious vascular complications.
  • A glycated hemoglobin target below 7% is widely recommended to prevent microvascular and macrovascular issues.
  • Evidence supporting intensive glycemic control for macrovascular disease prevention in type 2 diabetes is inconsistent.

Purpose of the Study:

  • To evaluate the effectiveness of intensive glycemic control in preventing vascular complications in type 2 diabetes.
  • To analyze recent trial data (ACCORD, ADVANCE, VADT) challenging traditional glycated hemoglobin targets.
  • To determine factors influencing the advisability of intensive glucose management.

Main Methods:

  • Review of clinical trial data on intensive glycemic control in type 2 diabetes.
  • Analysis of factors such as diabetes duration, pre-existing macrovascular disease, and comorbidities.
  • Assessment of the impact of intensive glucose management on microvascular and macrovascular outcomes.

Main Results:

  • Intensive glycemic control trials show benefits for microvascular disease but less clarity for macrovascular disease.
  • Recent studies (ACCORD, ADVANCE, VADT) question universal application of lower glycated hemoglobin targets.
  • Factors like diabetes duration, existing macrovascular disease, and comorbidities influence treatment outcomes.

Conclusions:

  • Lowering glycated hemoglobin to below 7% may not be universally beneficial for all type 2 diabetes patients.
  • Individualized glycated hemoglobin goals are crucial, considering patient-specific factors.
  • Personalized treatment strategies are necessary to optimize outcomes and minimize risks associated with intensive glucose management.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...